15 mg daily for 3 Moderate 10 mg once daily 15 mg once daily weeks, followed by 30 49 mL/min – 20 mg once daily Severe 10 mg once daily Xarelto is contraindicated (Use with caution) 15 29 mL/min – Severe Xarelto is contraindicated < 15 mL/min Patients above 65 years Based on clinical data, no dose adjustment is required for these patient populations (see Pharmacokinetic properties). Increasing age is associated with declining renal function. Body weight No dose adjustment is required for these patient populations (see Pharmacokinetic properties). Gender No dose adjustment is required for these patient populations (see Pharmacokinetic properties). Children and adolescents Xarelto is not recommended for use in children or adolescents below 18 years of age due to a lack of data on safety and efficacy. Ethnic differences No dose adjustment is required on ethnic differences (see Pharmacokinetic properties). Transition Xarelto from and to Vitamin K Antagonists (VKA) or Parenteral Anticoagulants Anticoagulant Transition From Xarelto Transition To Xarelto Vitamin K Transition from Xarelto to VKAs Transition from VKA to Xarelto: Antagonists There is a potential for inadequate For patients treated for prevention of (VKA) anticoagulation during the transition stroke and systemic embolism, VKA from Xarelto to VKA. Limited clinical treatment should be stopped and data is available to guide the Xarelto therapy should be initiated once process whereby patients are converted the INR is 3.0. ≤ from Xarelto to VKAs. For patients treated for DVT and prevention of recurrent DVT and PE, VKA treatment should be stopped and
Moderate 30 – 49 mL/min 10 mg once daily 15 mg once daily 15 mg daily for 3 weeks, followed by 20 mg once daily Severe 15 – 29 mL/min 10 mg once daily (Use with caution) Xarelto is contraindicated Severe < 15 mL/min Xarelto is contraindicated Patients above 65 years Based on clinical data, no dose adjustment is required for these patient populations (see Pharmacokinetic properties). Increasing age is associated with declining renal function. Body weight No dose adjustment is required for these patient populations (see Pharmacokinetic properties). Gender No dose adjustment is required for these patient populations (see Pharmacokinetic properties). Children and adolescents Xarelto is not recommended for use in children or adolescents below 18 years of age due to a lack of data on safety and efficacy. Ethnic differences No dose adjustment is required on ethnic differences (see Pharmacokinetic properties). Transition Xarelto from and to Vitamin K Antagonists (VKA) or Parenteral Anticoagulants Anticoagulant Transition From Xarelto Transition To Xarelto Vitamin K Antagonists (VKA) Transition from Xarelto to VKAs There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Limited clinical data is available to guide the process whereby patients are converted from Xarelto to VKAs. Transition from VKA to Xarelto: For patients treated for prevention of stroke and systemic embolism, VKA treatment should be stopped and Xarelto therapy should be initiated once the INR is ≤ 3.0. For patients treated for DVT and prevention of recurrent DVT and PE, VKA treatment should be stopped and
auspar-rivaroxaban-131002-pi.docx